Crispr Therapeutics AG (NASDAQ:CRSP) Director Kurt Von Emster sold 92,337 shares of the firm’s stock in a transaction on Friday, January 5th. The stock was sold at an average price of $26.96, for a total value of $2,489,405.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Kurt Von Emster also recently made the following trade(s):
- On Tuesday, January 2nd, Kurt Von Emster sold 37,754 shares of Crispr Therapeutics stock. The stock was sold at an average price of $26.76, for a total value of $1,010,297.04.
Shares of Crispr Therapeutics AG (NASDAQ CRSP) opened at $28.44 on Friday. Crispr Therapeutics AG has a 52 week low of $11.63 and a 52 week high of $28.97. The firm has a market capitalization of $1,170.00 and a price-to-earnings ratio of -88.88.
Crispr Therapeutics (NASDAQ:CRSP) last released its earnings results on Wednesday, November 8th. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.02). Crispr Therapeutics had a negative return on equity of 38.42% and a negative net margin of 466.58%. The business had revenue of $2.39 million during the quarter, compared to analysts’ expectations of $3.61 million. During the same quarter in the previous year, the business earned ($2.77) EPS. The business’s revenue for the quarter was up 54.2% on a year-over-year basis. analysts expect that Crispr Therapeutics AG will post -2.46 earnings per share for the current fiscal year.
A number of analysts recently issued reports on CRSP shares. Cann restated a “hold” rating on shares of Crispr Therapeutics in a research report on Sunday, December 10th. BidaskClub lowered Crispr Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, December 2nd. SunTrust Banks reiterated a “hold” rating and issued a $16.00 target price on shares of Crispr Therapeutics in a research note on Friday, November 10th. Piper Jaffray Companies started coverage on Crispr Therapeutics in a research note on Friday, December 22nd. They issued an “overweight” rating on the stock. Finally, Oppenheimer reiterated a “hold” rating on shares of Crispr Therapeutics in a research note on Thursday, December 21st. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $22.81.
A number of hedge funds have recently added to or reduced their stakes in the business. Wells Fargo & Company MN increased its stake in Crispr Therapeutics by 459.7% in the second quarter. Wells Fargo & Company MN now owns 7,987 shares of the company’s stock worth $128,000 after purchasing an additional 6,560 shares during the period. Capital Investment Advisory Services LLC purchased a new stake in Crispr Therapeutics in the third quarter worth $193,000. Ark Investment Management LLC purchased a new stake in Crispr Therapeutics in the second quarter worth $206,000. Moloney Securities Asset Management LLC purchased a new stake in Crispr Therapeutics in the third quarter worth $235,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of Crispr Therapeutics during the third quarter valued at $288,000. Institutional investors and hedge funds own 24.52% of the company’s stock.
WARNING: This story was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/01/12/insider-selling-crispr-therapeutics-ag-crsp-director-sells-2489405-52-in-stock.html.
About Crispr Therapeutics
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.